Patents by Inventor Scott Gallichan
Scott Gallichan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230302112Abstract: The present disclosure provides a respiratory syncytial virus (RSV) vaccine comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding an RSV F protein antigen, and methods of eliciting an immune response by administering said vaccine.Type: ApplicationFiled: November 4, 2022Publication date: September 28, 2023Inventors: Danilo Casimiro, Hardip Rajeshbhai Gopani, Joshua DiNapoli, Linong Zhang, Mark Parrington, Rebecca L. Goldman, Sudha Chivukula, William Scott Gallichan
-
Publication number: 20170157233Abstract: This disclosure relates to immunogenic compositions comprising an isolated immunogenic S. pneumoniae PcpA polypeptide, at least one additional antigen (such as for example, an isolated immunogenic S. pneumoniae polypeptide selected from the group consisting of the polyhistidine triad family of proteins (e.g., PhtD), and at least one isolated detoxified pneumolysin (e.g., PlyD1) and methods of using these compositions for preventing and treating diseases caused by S. pneumoniae.Type: ApplicationFiled: March 10, 2015Publication date: June 8, 2017Applicant: Sanofi Pasteur LimitedInventors: Scott Gallichan, Belma Ljutic, Martina Ochs-Onolemhemhen, Marie-Danielle Salha, Robert Hopfer, Lee-Jah Chang
-
Patent number: 9649372Abstract: This disclosure relates to adjuvants for use in immunogenic compositions comprising at least one antigen and an aluminum compound comprising hydroxyl groups that has been treated with phosphate, carboxylate, carbonate, sulfate diphosphonate or a mixture of two or more of these compounds and methods of using these compositions for preventing and treating diseases are also provided.Type: GrantFiled: December 20, 2010Date of Patent: May 16, 2017Assignee: SANOFI PASTEUR LIMITEDInventors: Kevin Harper, Belma Ljutic, Scott Gallichan, Martina Ochs-Onolemhemhen, Garry Morefield, Fernando Ausar, Marie-Danielle Salha
-
Publication number: 20160367655Abstract: The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis) in a subject, by administering to the subject a composition of the invention.Type: ApplicationFiled: March 21, 2016Publication date: December 22, 2016Inventors: Scott Gallichan, Ausra Mancevski, Nathalie Reveneau, Jin Su, Francois Dalencon, Jean Haensler
-
Patent number: 9327021Abstract: The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis) in a subject, by administering to the subject a composition of the invention.Type: GrantFiled: November 15, 2011Date of Patent: May 3, 2016Assignees: Sanofi Pasteur Limited, Sanofi Pasteur S.A.Inventors: Scott Gallichan, Ausra Mancevski, Nathalie Reveneau, Jin Su, Francois Dalencon, Jean Haensler
-
Publication number: 20150316567Abstract: This disclosure relates to methods for detecting the potency of a drug preparation and/or detecting antibodies in a host reactive against one or more antigens.Type: ApplicationFiled: December 13, 2014Publication date: November 5, 2015Applicant: SANOFI PASTEUR LIMITEDInventors: Marie-Danielle Salha, Scott Gallichan, Roger Brookes, Martina Ochs-Onolemhemhen
-
Patent number: 8946174Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: GrantFiled: September 23, 2010Date of Patent: February 3, 2015Assignee: Sanofi Pasteur LimitedInventors: Neil Berinstein, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan, Devender Singh-Sandhu, Raymond P. Oomen, Shi-Xian Cao
-
Patent number: 8802383Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.Type: GrantFiled: May 16, 2012Date of Patent: August 12, 2014Assignee: Sanofi Pasteur LimitedInventors: Neil Berinstein, Devender Satsangi Singh Sandhu, Corey Lovitt, Artur Pedyczak, Scott Gallichan, Laszlo Radvanyi
-
Publication number: 20130344109Abstract: The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis) in a subject, by administering to the subject a composition of the invention.Type: ApplicationFiled: November 15, 2011Publication date: December 26, 2013Applicants: SANOFI PASTEUR, S.A., SANOFI PASTEUR LIMITEDInventors: Scott Gallichan, Ausra Mancevski, Nathalie Reveneau, Jin Su, Francois Dalencon, Jean Haensler
-
Publication number: 20130183350Abstract: This disclosure relates to immunogenic compositions comprising an isolated immunogenic S. pneumoniae PcpA polypeptide and at least one additional antigen (such as for example, an isolated immunogenic S. pneumoniae polypeptide selected from the group consisting of the polyhistidine triad family of proteins (e.g. PhtD) and methods of using these compositions for preventing and treating diseases caused by S. pneumoniae.Type: ApplicationFiled: December 20, 2010Publication date: July 18, 2013Inventors: Kevin Harper, Belma Ljutic, Scott Gallichan, Martina Ochs-Onolemhemhen, Garry Morefield, Fernando Ausar, Marie-Danielle Salha
-
Publication number: 20130034579Abstract: This disclosure relates to adjuvants for use in immunogenic compositions comprising at least one antigen and an aluminum compound comprising hydroxyl groups that has been treated with phosphate, carboxylate, carbonate, sulfate diphosphonate or a mixture of two or more of these compounds and methods of using these compositions for preventing and treating diseases are also provided.Type: ApplicationFiled: December 20, 2010Publication date: February 7, 2013Inventors: Kevin Harper, Belma Ljutic, Scott Gallichan, Martina Ochs-Onolemhemhen, Garry Morefield, Fernando Ausar, Marie-Danielle Salha
-
Patent number: 8361706Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.Type: GrantFiled: July 14, 2010Date of Patent: January 29, 2013Assignee: Sanofi Pasteur LimitedInventors: Neil Berinstein, Devender Singh-Sandhu, Corey Lovitt, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan
-
Publication number: 20130011422Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: ApplicationFiled: May 31, 2012Publication date: January 10, 2013Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Laszlo Radvanyi, Devender Singh-Sandhu
-
Publication number: 20120295275Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.Type: ApplicationFiled: May 16, 2012Publication date: November 22, 2012Applicant: Sanofi Pasteur, Ltd.Inventors: Neil Berinstein, Devender Satsangi Singh Sandhu, Corey Lovitt, Artur Pedyczak, Scott Gallichan, Laszlo Radvanyi
-
Patent number: 8207314Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: GrantFiled: April 15, 2004Date of Patent: June 26, 2012Assignee: Sanofi Pasteur LimitedInventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Laszlo Radvanyi, Devender Singh-Sandhu
-
Publication number: 20110311543Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: ApplicationFiled: August 23, 2011Publication date: December 22, 2011Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Parrington Mark, Artur Pedyczak, Laszio Radvanyi, Devender Singh-Sandhu
-
Patent number: 8021664Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: GrantFiled: April 15, 2004Date of Patent: September 20, 2011Assignee: Sanofi Pasteur LimitedInventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Devender Singh-Sandhu
-
Publication number: 20110117640Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: ApplicationFiled: September 23, 2010Publication date: May 19, 2011Inventors: Neil Berinstein, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan, Devender Singh-Sandhu, Raymond P. Oomen, Shi-Xian Cao
-
Patent number: 7851213Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: GrantFiled: July 1, 2003Date of Patent: December 14, 2010Assignee: Sanofi Pasteur LimitedInventors: Neil Berinstein, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan, Devender Singh-Sandhu, Raymond P. Oomen, Shi-Xian Cao
-
Publication number: 20100278848Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: ApplicationFiled: April 15, 2004Publication date: November 4, 2010Applicant: AVENTIS PASTEUR, INC.Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Laszlo Radvanyi, Devender Singh-Sandhu